8-Bromination of 2,6,9-trisubstituted purines with pyridinium tribromide  by Bliman, David et al.
Tetrahedron Letters 55 (2014) 2929–2931Contents lists available at ScienceDirect
Tetrahedron Letters
journal homepage: www.elsevier .com/ locate/ tet le t8-Bromination of 2,6,9-trisubstituted purines with pyridinium
tribromidehttp://dx.doi.org/10.1016/j.tetlet.2014.03.084
0040-4039/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Tel.: +46 31 7869017.
E-mail address: grotli@cmb.gu.se (M. Grøtli).
 The authors contributed equally to this work.
N
N NH
N
7
8
9
1
2
3
4
5
6
Figure 1. Purine core structure with atom numbering.
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Scheme 1. Pyridinium tribromide (PyrBr3) in equilibrium with brom
pyridinium bromide.David Bliman , Mariell Pettersson , Mattias Bood, Morten Grøtli ⇑
Department of Chemistry & Molecular Biology, University of Gothenburg, Kemivägen 10, SE-412 96 Gothenburg, Sweden
a r t i c l e i n f oArticle history:
Received 5 December 2013
Revised 24 February 2014
Accepted 18 March 2014
Available online 25 March 2014
Keywords:
Bromination
Halogenation
Purines
Pyridinium tribromide
Pyridine perbromide hydrobromidea b s t r a c t
2,6,9-Trisubstituted purines are brominated in high yields using pyridinium tribromide as the
brominating reagent. This procedure works excellently for electron-rich purines having electron-
donating substituents at the 2- and 6-positions. The use of pyridinium tribromide, a crystalline
alternative to elemental bromine, improves the bromination procedure for this type of substrate as the
reagent is easy to handle and the work-up and puriﬁcation procedures are simpliﬁed.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Purines (Fig. 1) are found naturally in compounds key to life
such as ATP, DNA (adenosine and guanosine), and NAD.1 The
biological importance of naturally occurring purines has led to an
interest in studies of the biological activity of synthetically
modiﬁed purines.2 Examples include protein kinase inhibitors,3,4
adenosine receptor modulators,5 adenylation enzyme inhibitors,6
and fructose bisphosphatase inhibitors.7
The bioactivity of purines has spurred efforts in developing
methods to control selectively the substitution pattern of the
purine ring system.8 Purines are commonly substituted at the 2-,
6-, 8-, and 9-positions (see Fig. 1).8,9 While purines with either
amino or chloro substituents at the 2- and/or 6-positions are com-
mercially available, the 8-position generally needs to be activated
to affect substitution. Except for a few recent examples of direct
CAH activation,10,11 the 8-position is commonly activated by
halogenation followed by nucleophilic aromatic substitution12 or
palladium-catalyzed cross-coupling. Examples of the latter include
Sonogashira,13 Suzuki14,15 and Stille12,16 type couplings to intro-
duce alkynyl, aryl, and alkenyl substituents, respectively.
Commonly, Br212 and NBS17,18 are used as reagents for the
8-bromination of purines. The use of sodium monobromoisocyan-
urate19 and 1,3-dibromo-5,5-dimethyl hydantoin20 have also been
reported for the bromination of nucleobases including adenosine.
An excess of the brominating reagent is often used, and aselemental bromine is toxic and corrosive it becomes inconvenient
to work with. In this Letter, we evaluate pyridinium tribromide as a
brominating reagent for a range of purine derivatives. Pyridinium
tribromide (PyrBr3) has been utilized for the bromination of
indoles21 and other aryl compounds,22,23 the a-position of
ketones24–26 and also alkenes.27,28 It is a solid which can be
weighed in air and is easily handled. In solution, PyrBr3 is in
equilibrium with pyridinium bromide and Br2 (Scheme 1) and
the distribution is reported to be dependent on the polarity of
the solvent.29 Both PyrBr3 and Br2 act as brominating agents.ine and
2930 D. Bliman et al. / Tetrahedron Letters 55 (2014) 2929–2931In an ongoing study of 2,6,8,9-tetrasubstituted purines we
needed a protocol that would allow selective bromination at the
8-position of purines in the presence of aromatic substituents.
We turned ﬁrst to the commonly used methods for purine deriva-
tives. In our model reaction, bromination of 1a (Table 1, entry 1)
using NBS in acetonitrile at room temperature30 resulted in only
a 25% isolated yield of 2a; para-bromination of the phenyl also
occurred in trace amounts according to 1H NMR spectroscopy.
Reaction of purine 1a with Br2 in NaOAc/HOAc buffer in THF/
MeOH12,31 resulted in a 30% yield of 2a. However, when 1a was
treated with PyrBr3 in CH2Cl2 at room temperature for 5 h, 2a
was isolated in 93% yield (Table 1, entry 1).32 In addition to the
higher yield, the workup, and puriﬁcation of the PyrBr3 reactions
are more convenient than for reactions involving elemental Br2.
These results encouraged us to explore the scope of PyrBr3 as a
brominating reagent for the 8-bromination of purines. The results
are summarized in Table 1. Initially, we wanted to investigate if the
method was applicable to purines lacking substituents at the 9-po-
sition. This is of interest since it allows insertion of bromine early
in a reaction sequence and paves the way for subsequent diversiﬁ-
cation. Treating 6-chloropurine (1b) and 2-amino-6-chloropurine
(1c) with PyrBr3 in CH2Cl2 did not result in any or only a trace
amount of bromination (entries 2 and 3). Since these compounds
are largely insoluble in CH2Cl2, the reactions were also run in
DMF, but without success (results not shown). Bromination of 1d
in DMF gave the product in 38% yield (entry 4). Although 1d was
poorly soluble in CH2Cl2, 2d was obtained in 46% isolated yieldTable 1
8-Bromination of purines using PyrBr3
N
N N
N
R6
R2
CH2Cl2,
R9
PyrBr3
1
Entry Substratea R6 R2 R9
1 1a N(Me)2 NH2 Phenethy
2 1b Cl H H
3 1c Cl NH2 H
4 1d N(Me)2 NH2 H
5 1d N(Me)2 NH2 H
6 1e NH2 H Bn
7 1f Cl H Bn
8 1g OMe H Bn
9 1h N(Me)2 H Bn
10 1i N(Me)2 NH2 Bn
11 1j NHBn NH2 Bn
12 1k NH2 NH2 Bn
13 1l N(Me)2 NH2 i-Bu
14 1m N(Me)2 NHBn Phenethy
15 1n NHBn NHBoc Bn
16 1i N(Me)2 NH2 Bn
17 1a N(Me)2 NH2 Phenethy
18 1i N(Me)2 NH2 Bn
19 1o OMe NH2 Bn
20 1o OMe NH2 Bn
21 1p Cl NH2 Bn
22 1i N(Me)2 NH2 Bn
a Protocols for brominations, synthesis of non-commercially available starting ma
Information.
b Isolated yield.
c nr = no reaction, that is, only starting material was observed by LCMS and/or TLC.
d o.n = overnight.
e Only a trace amount of the product was observed by LCMS.
f 3 equiv of PyrBr3 were used.
g Polymer supported PyrBr3 was used.after 55 h at room temperature (entry 5). Therefore, compounds
lacking a substituent at the 9-position did not react or provided
unsatisfactory yields.
Next, we introduced substituents at the 9-position. Bromination
of purines not substituted at the 2-position (1e–h) was unsuccess-
ful using PyrBr3 in CH2Cl2 at room temperature (entries 6–9). The
bromination of 9-benzyladenine (1f) was also performed in DMF
at both room temperature and 60 C, but no product was observed.
Lewis acids (TMS-triﬂate and BBr3) have been reported to increase
the rate of bromination reactions on similar substrates,20 but failed
to result in more than a trace amount of brominated material (as
observed by LCMS) in this case.
2,6-Diaminopurines (1i,j and 1l,m) were brominated in high
yields (80–91%) with PyrBr3 in CH2Cl2 at room temperature
(entries 10, 11, 13, and 14). 2,6-Diaminopurine 1k has poor
solubility in CH2Cl2, but can be brominated in DMF, although with
a signiﬁcantly lower yield (27%, entry 12) compared to the
bromination of electron-rich purines soluble in CH2Cl2 (1i,j and
1l,m). When a tert-butyloxycarbamoyl group was introduced at
the C2 position (entry 15) as in 1n, treatment with PyrBr3 gave
2n in 36% isolated yield. The conversion was however not complete
after 3 h and the protecting group was partially cleaved under
these conditions. For 9-substituted 2,6-diaminopurines (1i and
1a), changing the solvent to DMF resulted in lower yields (entries
16 and 17) compared to CH2Cl2 (entries 10 and 1). In addition,
acetonitrile as the solvent resulted in a comparable yield to
reactions in CH2Cl2, but the reaction was slower (entry 18). r.t.
N
N N
N
R6
R2
Br
R9
2
Solvent Time (h) Product Yieldb (%)
l CH2Cl2 5 2a 93
CH2Cl2 24 2b nrc
CH2Cl2 o.nd 2c Tracee
DMF 6 2d 38
CH2Cl2 55 2d 46
CH2Cl2 48 2e nr
CH2Cl2 o.n 2f nr
CH2Cl2 o.n 2g nr
CH2Cl2 o.n 2h Trace
CH2Cl2 3 2i 90
CH2Cl2 3 2j 87
DMF 5 2k 27
CH2Cl2 2.5 2l 80
l CH2Cl2 1 2m 91
CH2Cl2 3 2n 36
DMF 3 2i 47
l DMF 3 2a 59
MeCN o.n 2i 80
CH2Cl2 o.n 2o 37
CH2Cl2 o.n 2o 43f
CH2Cl2 16 2p nr
CH2Cl2 4 2i 93g
terials, and data from product characterization are available in the Supporting
D. Bliman et al. / Tetrahedron Letters 55 (2014) 2929–2931 2931When 2-amino-6-methoxypurine (1o) was treated with PyrBr3,
2o was isolated in 37% yield (entry 19). Increasing the equivalents
of PyrBr3 did not affect the yield of 2o (entry 20). No bromination
occurred on 2-amino-9-benzyl-6-chloropurine (1p), indicating that
an electron-withdrawing substituent at the 6-position was not
tolerated (entry 21). Furthermore, comparison of entry 8 with 11,
and entry 9 with 12 clearly shows that the C2 amino group is
necessary for bromination to occur under these conditions.
PyrBr3 is also commercially available on a polymer support. The
use of the polymer-supported reagent for the bromination of 1i
worked as equally well as the solution phase reaction; 2i was
isolated in 93% yield (entry 22). In addition, the solution phase
reaction could be scaled up to 0.5 g without any decrease in the
yield or purity.
In conclusion, we have presented a procedure for the 8-bromin-
ation of 2,6,9-trisubstituted purines using PyrBr3, a crystalline
alternative to elemental bromine. The reactions of electron-rich
purine derivatives are typically completed in one to ﬁve hours
and the products are isolated in high yields after column chroma-
tography. Other aromatic substituents that are present on the
substrate are not brominated under these conditions. The reaction
is limited to purines with electron-donating substituents at the
2- and 6-postions. We are currently utilizing this method for the
bromination of 2,6,9-trisubstituted purines to obtain a library of
highly functionalized biologically active purines.
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